Almirall has opened a new affiliate in Toronto, Canada. Having a presence in Canada will help the company roll out its recently approved aclidinium DPI for COPD, among other drugs, Almirall says. The company will co-market aclidinium as Tudorza Pressair with Forest Laboratories. In Europe, aclidinium bromide inhalers are being marketed as the Eklira Genuair and … [Read more...] about Almirall opens Canadian affiliate, presents positive Phase 3 results for Eklira Genuair
Business
Australian court issues injunction against Apotex in Nasonex case
The Federal Court of Australia has granted an injunction against Apotex, banning it from selling generic mometasone furoate nasal sprays in the country pending the outcome of a patent infringement lawsuit by Merck Sharpe & Dohme Australia. Apotex, which claims that MSD's patent is invalid, had already begun marketing the nasal sprays and intended to begin shipping … [Read more...] about Australian court issues injunction against Apotex in Nasonex case
Elevation to be acquired by Sunovion
Elevation Pharmaceuticals, which is developing several inhalation products, has agreed to be acquired by Sunovion. Both boards have approved the deal. The agreement includes an upfront payment of $100 million and milestone payments for development of Elevation's EP-101 glycopyrrolate inhalation solution that could total as much as $90 million. EP-101 is currently … [Read more...] about Elevation to be acquired by Sunovion
Bend Research opens new spray drying facility
Bend Research has announced the addition of a new stand-alone cGMP spray-drying facility for high potency drug development and manufacturing, including inhalation biotherapeutics. The company offers a range of development and particle engineering services for OINDPs. Bend Research CEO Rod Ray said, “We’re excited to offer our clients expanded cGMP spray-drying … [Read more...] about Bend Research opens new spray drying facility
Research firm predicts global asthma and COPD market will reach $47 billion by 2017
A new research report titled "Global Markets for Asthma & COPD Drugs" from RnRMarketResearch.com projects that the global market for prescription asthma and COPD drugs will rise from almost $35 billion in 2011 to $38 billion in 2012 and just over $47 billion in 2017. The report predicts that asthma drug sales alone will reach $20.2 billion in 2017, up from $15.3 … [Read more...] about Research firm predicts global asthma and COPD market will reach $47 billion by 2017
Nephron announces launch of OTC asthma inhalation product
Florida-based Nephron Pharmaceuticals has announced that it is launching an over-the-counter racepinephrine inhalation solution delivered by a device called the EZ Breathe Atomizer. The product will be marketed as Asthmanefrin and is being promoted as a substitute for the banned CFC Primatene Mist inhaler. According to the company, the product will be available at … [Read more...] about Nephron announces launch of OTC asthma inhalation product
Watson launches authorized generic levalbuterol inhalation solution
Watson Pharmaceuticals has launched a generic levalbuterol inhalation solution, an authorized version of Sunovion's Xopenex for the treatment of asthma. Shipments will begin immediately. The company cites IMS Health data saying that sales of Xopenex for the past 12 months were approximately $474 million. Read the Watson press release. … [Read more...] about Watson launches authorized generic levalbuterol inhalation solution
Novartis reaffirms that respiratory research is to remain in Horsham, UK
According to a newspaper report, Novartis has confirmed that it will retain its respiratory disease research center in Horsham, UK, with 440 employees. The company will sell a portion of the site and plans to invest approximately £5 million to renovate some of the remaining buildings. In March 2011, Novartis announced significant personnel reductions at the site … [Read more...] about Novartis reaffirms that respiratory research is to remain in Horsham, UK
$7.5 million in new financing for Trimel Pharmaceuticals
GE Capital Healthcare Financial Services has announced today that it is providing $7.5 million in financing to Trimel Pharmaceuticals for Phase 2 and 3 clinical development of several OINDPs. Trimel's pipeline includes asthma and allergic rhinitis therapies based on its Trivair dry powder inhaler technology and male and female sexual dysfunction therapies based on its … [Read more...] about $7.5 million in new financing for Trimel Pharmaceuticals
Chiesi to distribute Kamada’s inhaled AAT
Israeli biopharmaceutical company Kamada will receive milestone payments of $60 million as part of a 12-year distribution agreement with Chiesi Farmaceutici for Kamada's inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency (AATD-IH). Chiesi will distribute the inhalation solution in Europe, Turkey and former CIS countries. Kamada expects … [Read more...] about Chiesi to distribute Kamada’s inhaled AAT